在转移性黑色素瘤中准RAF1基因融合与MEK抑制
Karam Khaddour1,2,3, Rizwan Haq1,2,3, Elizabeth I Buchbinder1,2,3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.
The oncologist
|November 6, 2024
概括
黑色素瘤患者的RAF1基因融合可能对向治疗有反应. MEK 抑制剂表现出抗瘤活性,这表明它们可用于RAF1基因融合患者.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在黑色素瘤中基因融合的临床意义仍然不清楚.
- 临床前数据表明,RAF1基因融合可能是治疗的目标.
研究的目的:
- 研究RAF1基因融合在黑色素瘤中的临床相关性和治疗潜力.
- 评估针对性治疗在患有 RAF1 基因融合的黑色素瘤患者中的疗效.
主要方法:
- 对1268名黑色素瘤患者的回顾性审查,具有针对性测序数据.
- 9例RAF1基因融合病例的鉴定和临床病理学表征.
- 将数据与已发表的关于针对RAF1基因融合的向疗法的报告进行整合.
主要成果:
- 确定了9例RAF1基因融合的黑色素瘤病例.
- 两名接受MEK抑制剂治疗的患者经历了良好的结果,其中包括一个持久反应.
- 聚合数据表明单剂MEK抑制的抗瘤活性.
结论:
- 单剂MEK抑制在RAF1基因融合的黑色素瘤患者中显示出抗瘤活性.
- 患有RAF1基因融合的患者应考虑使用MEK抑制剂治疗.
相关概念视频
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


